Targeting Cancer Survival Genes in Solid Tumors

NUAgo Therapeutics CEO and Co-Founder, Robert Schickel, Ph.D., joins Daniel Levine on The Bio Report to discuss short RNA constructs that silence multiple cancer survival genes at once, with lead programs targeting liver, ovarian, and prostate cancers.